Faisalabad histiocytosis

Faisalabad histiocytosis, also known as familial histiocytosis with sensorineural deafness, is an extremely rare autosomal recessive disorder first described in consanguineous families from Faisalabad, Pakistan. It is classified as a non-Langerhans cell histiocytosis and is caused by biallelic mutations in the SLC29A3 gene, which encodes the human equilibrative nucleoside transporter 3 (hENT3). This gene is also implicated in a spectrum of related conditions sometimes referred to as SLC29A3 spectrum disorder, including H syndrome and pigmented hypertrichosis with insulin-dependent diabetes mellitus (PHID) syndrome. The disease primarily affects the skin, lymph nodes, and auditory system. Key clinical features include widespread lymphadenopathy (swollen lymph nodes), sensorineural hearing loss (deafness), and joint swelling or contractures. Histiocytic infiltration — the abnormal accumulation of immune cells called histiocytes — is found in lymph nodes and other tissues. Additional features may include hepatosplenomegaly (enlarged liver and spleen) and skin manifestations. The condition typically presents in infancy or early childhood. There is currently no specific curative treatment for Faisalabad histiocytosis. Management is supportive and symptomatic, focusing on addressing hearing loss with hearing aids or cochlear implants, managing joint complications, and monitoring for organ involvement. Genetic counseling is recommended for affected families. Due to the extreme rarity of this condition, clinical experience is limited, and long-term outcomes are not well characterized. Research into the broader SLC29A3 spectrum disorders may provide further insights into potential therapeutic approaches in the future.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Faisalabad histiocytosis